Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases

25 Jul 2017

Nektar taps into Lilly's immunology know-how for fast development of NKTR-358, which targets IL-2 to stimulate the body's own inflammation-inhibiting Tregs rather than suppress the immune system.

Business partners hands on top of each other symbolizing companionship

Lilly, Nektar Partner On 'Stimulating' IL-2 Drug In Autoimmune Diseases

More from Deals

More from Business